News Center

News Center

News Center

First Patient Dosed in Global Pivotal Phase 3 Clinical Trial for BioNTech and DualityBio’s B7-H3 ADC DB-1311/BNT324 in Metastatic Castration-Resistant Prostate Cancer

2025-09-05

DualityBio and BioNTech Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer
2025-07-22

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
2025-07-09

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
2025-06-05

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
2025-05-22

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
2025-04-30

DualityBio 2024 Environmental. Social and Governanee Report

«
1
2
3
4
5
6
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai